• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Growing Public Awareness Will Uplift the Global Stem Cell Umbilical Cord Blood Market Through 2019: Technavio

    Growing Public Awareness Will Uplift the Global Stem Cell Umbilical Cord Blood Market Through 2019: Technavio

  2. Research and Markets: Prostate Cancer - Pipeline Review, H1 2015

    Research and Markets: Prostate Cancer - Pipeline Review, H1 2015

  3. Research and Markets: Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of Nearly 60%

    Research and Markets: Analyzing the Global Biotechnology Industry 2015 - The Medical/Healthcare Segment is the Leading Segment of the Biotechnology Industry Consisting of Nearly 60%

  4. Bull case strengthens as summer cross currents -2-

    Bull case strengthens as summer cross currents -2-

  5. Celgene Receives Antitrust Clearance for Receptos Acquisition

    Celgene Receives Antitrust Clearance for Receptos Acquisition

  6. UPDATE: Charting the U.S. markets' technical cross currents

    UPDATE: Charting the U.S. markets' technical cross currents

  7. Charting the U.S. markets' technical cross currents

    Charting the U.S. markets' technical cross currents

  8. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  9. Tuttle Tactical Management Weekly Market Notes

    Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...

  10. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.